<code id='6197373357'></code><style id='6197373357'></style>
    • <acronym id='6197373357'></acronym>
      <center id='6197373357'><center id='6197373357'><tfoot id='6197373357'></tfoot></center><abbr id='6197373357'><dir id='6197373357'><tfoot id='6197373357'></tfoot><noframes id='6197373357'>

    • <optgroup id='6197373357'><strike id='6197373357'><sup id='6197373357'></sup></strike><code id='6197373357'></code></optgroup>
        1. <b id='6197373357'><label id='6197373357'><select id='6197373357'><dt id='6197373357'><span id='6197373357'></span></dt></select></label></b><u id='6197373357'></u>
          <i id='6197373357'><strike id='6197373357'><tt id='6197373357'><pre id='6197373357'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:leisure time    Page View:3518
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In